MedTrace Logo

Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin

NCT07682454 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-07-02

No results posted yet for this study

Summary

This is a single-arm, open-label, single-center, first-in-human feasibility study evaluating parenchymal blood volume (PBV) imaging as a tool to dynamically assess perfusional changes in hepatocellular carcinoma (HCC) potentiated by intra-arterial administration of nitroglycerin.

Conditions

  • Hepatocellular Carcinoma (HCC)
  • Liver Cancer, Adult

Interventions

PROCEDURE

Parenchymal Blood Volume (PBV) Imaging

Undergo imaging

DRUG

Nitroglycerin

Given Intra-Arterially

OTHER

Medical Record Review

Data will be collected from the participant medical records.

Sponsors & Collaborators

Principal Investigators

  • Christopher Brunson, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2029-02-01
Completion
2030-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07682454 on ClinicalTrials.gov